Cardiovascular Nuclear Medicine
J15 · Effective Oct 1, 2015
18 active Medicare policies list J3490, and 136 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
J15 · Effective Oct 1, 2015
JE · Effective Oct 1, 2015
JF · Effective Oct 1, 2015
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
J15 · Effective Oct 1, 2015
JE · Effective Jul 12, 2016
JF · Effective Jul 12, 2016
JJ · Effective Feb 13, 2022
136 policies from 13 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Showing 10 of 20 · All BCBS Illinois policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Corneal Collagen Cross-Linking | May 1, 2026 | Covered |
| Cosmetic and Reconstructive Procedures | Jan 1, 2026 | Covered |
| Denosumab and Biosimilars for Non-Oncologic Indications | Jan 1, 2026 | Covered |
| Eculizumab and Associated Biosimilar(s) | Dec 1, 2025 | Covered |
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Esketamine Nasal Spray |
JM · Effective Feb 13, 2022
National · Effective Jun 12, 2025
National · Effective Jan 29, 2026
National · Effective Oct 1, 2026
National · Effective Dec 26, 2024
J6 · Effective Jul 1, 2026
National · Effective Apr 16, 2026
National · Effective Oct 16, 2025
National · Effective Oct 1, 2026
| Jan 1, 2026 |
| Covered |
| Etranacogene dezaparvovec-drlb | Jan 1, 2026 | Covered |
|---|
| FDA - Drugs, Biologicals, Cellular and Gene Therapies | Aug 1, 2026 | Covered |
|---|
| Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency | Nov 15, 2025 | Covered |
|---|
| Human Growth Hormone (GH) | Jan 1, 2026 | Covered |
|---|
Showing 10 of 20 · All BCBS Montana policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Corneal Collagen Cross-Linking | May 1, 2026 | Covered |
| Cosmetic and Reconstructive Procedures | Jan 1, 2026 | Covered |
| Denosumab and Biosimilars for Non-Oncologic Indications | Jan 1, 2026 | Covered |
| Eculizumab and Associated Biosimilar(s) | Dec 1, 2025 | Covered |
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Esketamine Nasal Spray | Jan 1, 2026 | Covered |
| Etranacogene dezaparvovec-drlb | Jan 1, 2026 | Covered |
| FDA - Drugs, Biologicals, Cellular and Gene Therapies | Aug 1, 2026 | Covered |
| Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency | Nov 15, 2025 | Covered |
| Human Growth Hormone (GH) | Jan 1, 2026 | Covered |
Showing 10 of 20 · All BCBS New Mexico policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Corneal Collagen Cross-Linking | May 1, 2026 | Covered |
| Cosmetic and Reconstructive Procedures | Jan 1, 2026 | Covered |
| Denosumab and Biosimilars for Non-Oncologic Indications | Jan 1, 2026 | Covered |
| Eculizumab and Associated Biosimilar(s) | Dec 1, 2025 | Covered |
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Esketamine Nasal Spray | Jan 1, 2026 | Covered |
| Etranacogene dezaparvovec-drlb | Jan 1, 2026 | Covered |
| FDA - Drugs, Biologicals, Cellular and Gene Therapies | Aug 1, 2026 | Covered |
| Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency | Nov 15, 2025 | Covered |
| Human Growth Hormone (GH) | Jan 1, 2026 | Covered |
Showing 10 of 20 · All BCBS Oklahoma policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Corneal Collagen Cross-Linking | May 1, 2026 | Covered |
| Cosmetic and Reconstructive Procedures | Jan 1, 2026 | Covered |
| Denosumab and Biosimilars for Non-Oncologic Indications | Jan 1, 2026 | Covered |
| Eculizumab and Associated Biosimilar(s) | Dec 1, 2025 | Covered |
| Enzyme-Replacement Therapy for Lysosomal Storage Disorders | Jan 1, 2026 | Covered |
| Esketamine Nasal Spray | Jan 1, 2026 | Covered |
| Etranacogene dezaparvovec-drlb | Jan 1, 2026 | Covered |
| FDA - Drugs, Biologicals, Cellular and Gene Therapies | Aug 1, 2026 | Covered |
| Gene Therapy for Aromatic L-amino Acid Decarboxylase Deficiency | Nov 15, 2025 | Covered |
| Human Growth Hormone (GH) | Jan 1, 2026 | Covered |
Showing 10 of 13 · All UMR (UnitedHealthcare) policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Chelation Therapy | Jul 1, 2026 | Covered |
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |
| Ketalar (Ketamine) and Spravato (Esketamine) | May 1, 2026 | Covered |
| Lumvoa (Veligrotug-Vvze) and Tepezza (Teprotumumab-Trbw) | Oct 1, 2026 | Covered |
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Oxlumo (Lumasiran) and Rivfloza (Nedosiran) | Jun 1, 2026 | Covered |
| Papzimeos (Zopapogene Imadenovec-Drba) | Apr 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Review at Launch for New to Market Medications | Dec 1, 2025 | Covered |
| Sodium Hyaluronate | Oct 1, 2026 | Covered |
Showing 10 of 13 · All UnitedHealthcare policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Chelation Therapy | Jul 1, 2026 | Covered |
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |
| Ketalar (Ketamine) and Spravato (Esketamine) | May 1, 2026 | Covered |
| Lumvoa (Veligrotug-Vvze) and Tepezza (Teprotumumab-Trbw) | Oct 1, 2026 | Covered |
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Oxlumo (Lumasiran) and Rivfloza (Nedosiran) | Jun 1, 2026 | Covered |
| Papzimeos (Zopapogene Imadenovec-Drba) | Apr 1, 2026 | Covered |
| Provider Administered Drugs – Site of Care | Oct 1, 2026 | Covered |
| Review at Launch for New to Market Medications | Dec 1, 2025 | Covered |
| Sodium Hyaluronate | Oct 1, 2026 | Covered |
Showing 10 of 12 · All Surest (UnitedHealthcare) policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Chelation Therapy | Jul 1, 2026 | Covered |
| Clotting Factors, Coagulant Blood Products, & Other Hemostatics | Oct 1, 2026 | Covered |
| Ketalar (Ketamine) and Spravato (Esketamine) | May 1, 2026 | Covered |
| Lumvoa (Veligrotug-Vvze) and Tepezza (Teprotumumab-Trbw) | Oct 1, 2026 | Covered |
| Medical Therapies for Enzyme Deficiencies | Oct 1, 2026 | Covered |
| Oxlumo (Lumasiran) and Rivfloza (Nedosiran) | Jun 1, 2026 | Covered |
| Papzimeos (Zopapogene Imadenovec-Drba) | Apr 1, 2026 | Covered |
| Review at Launch for New to Market Medications | Dec 1, 2025 | Covered |
| Sodium Hyaluronate | Oct 1, 2026 | Covered |
| Subcutaneous Implantable Naltrexone Pellets | Jan 1, 2026 | Covered |
Showing 10 of 11 · All Anthem policies
| Policy | Effective | Status of J3490 |
|---|---|---|
| Autologous Adipose-derived Regenerative Cell Therapy | Jan 6, 2026 | Not covered |
| Cellular Therapy Products for Allogeneic Stem Cell Transplantation | Oct 1, 2026 | Covered |
| Drug-Eluting Devices for Maintaining Sinus Ostial Patency | Apr 15, 2026 | Not covered |
| Gene Therapy for Aromatic L-Amino Acid Decarboxylase Deficiency | Apr 15, 2026 | Not covered |
| Gene Therapy for Beta Thalassemia | Aug 27, 2026 | Covered |
| Gene Therapy for Duchenne Muscular Dystrophy | Oct 1, 2026 | Covered |
| Gene Therapy for Hemophilia | May 28, 2026 | Covered |
| Gene Therapy for Ocular Conditions | Apr 15, 2026 | Covered |
| Gene Therapy for Sickle Cell Disease | Aug 27, 2026 | Covered |
| Gene Therapy for Spinal Muscular Atrophy | Jul 1, 2026 | Covered |
| Policy | Effective | Status of J3490 |
|---|---|---|
| Amtagvi (lifileucel) | Aug 3, 2026 | Covered |
| Gene Therapy Treatments for Sickle Cell Disease | Feb 2, 2026 | Covered |
| Kebilidi (eladocagene exuparvovec-tneq) | Mar 2, 2026 | Covered |
| Policy | Effective | Status of J3490 |
|---|---|---|
| Cigna MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J3490 |
|---|---|---|
| Q4 - 2026 JHP MedOnc Master Drug List.pdf | Not recorded | Prior auth required |
| Policy | Effective | Status of J3490 |
|---|---|---|
| Placental and Umbilical Cord Blood as a Source of Stem Cells | May 1, 2026 | Covered |
| Policy | Effective | Status of J3490 |
|---|---|---|
| Medications/Drugs (Outpatient/Part B) | Not recorded | Covered |